GYRE Stock Summary and Trading Ideas (Gyre Therapeutics | NASDAQ:GYRE)

Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.

Gyre Therapeutics trades on the NASDAQ stock market under the symbol GYRE.

As of January 17, 2025, GYRE stock price climbed to $10.95 with 47,598 million shares trading.

GYRE has a market cap of $939.75 million. This is considered a Small Cap stock.

The top ETF exchange traded funds that GYRE belongs to (by Net Assets): VXF, IWM, SCHA, IWN, VTWO.

GYRE has underperformed the market in the last year with a return of -52.6%, while the SPY ETF gained +28.0%. In the last 3 month period, GYRE fell short of the market, returning -21.9%, while SPY returned +3.0%. However, in the most recent 2 weeks GYRE has outperformed the stock market by returning +1.5%, while SPY returned +1.0%.

GYRE support price is $10.05 and resistance is $11.55 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GYRE shares will trade within this expected range on the day.